BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions. The company's other therapeutic candidates comprise BL-1040, a resorbable polymer solution for use in the prevention of ventricular remodeling; BL-9020, which is a monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; and BL-1230, a cannabinoid receptor type 2 intended as an anti-inflammatory treatment for dry eye syndrome. The company has collaboration agreement with Novartis Pharma AG to facilitate development and commercialization of Israeli-sourced drug candidates; MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's Atezolizumab in various Phase 1b/2 studies for in various solid tumors and hematologic malignancies. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi'in, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLRX
Previous Symbol
CUSIPN/A
Phone972-2548-9100
Debt
Debt-to-Equity RatioN/A
Current Ratio8.03
Quick Ratio8.03
Price-To-Earnings
Trailing P/E Ratio-3.26
Forward P/E Ratio-4.01
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.50 per share
Price / Book1.76
Profitability
EPS (Most Recent Fiscal Year)($0.27)
Net Income$-24,350,000.00
Net MarginsN/A
Return on Equity-49.42%
Return on Assets-43.48%
Miscellaneous
Employees51
Outstanding Shares106,490,000
Market Cap$104.36 million
OptionableN/A
BIOLINERX Ltd/S (NASDAQ:BLRX) Frequently Asked Questions
What is BIOLINERX Ltd/S's stock symbol?
BIOLINERX Ltd/S trades on the NASDAQ under the ticker symbol "BLRX."
How were BIOLINERX Ltd/S's earnings last quarter?
BIOLINERX Ltd/S (NASDAQ:BLRX) issued its earnings results on Monday, August, 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.06) by $0.01. View BIOLINERX Ltd/S's Earnings History.
When is BIOLINERX Ltd/S's next earnings date?
What price target have analysts set for BLRX?
4 brokers have issued 1-year price objectives for BIOLINERX Ltd/S's shares. Their predictions range from $2.00 to $4.00. On average, they expect BIOLINERX Ltd/S's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 240.4% from the stock's current price. View Analyst Price Targets for BIOLINERX Ltd/S.
What is the consensus analysts' recommendation for BIOLINERX Ltd/S?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLINERX Ltd/S in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIOLINERX Ltd/S.
What are Wall Street analysts saying about BIOLINERX Ltd/S stock?
Here are some recent quotes from research analysts about BIOLINERX Ltd/S stock:
- 1. According to Zacks Investment Research, "Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. " (10/15/2018)
- 2. Maxim Group analysts commented, "BioLineRx reported 2Q18 with expenses of $5.7M and ended the quarter with $41M in cash on the balance sheet. We estimate that the company has runway into 2020." (8/13/2018)
- 3. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $4 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, BL-8040. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (7/30/2018)
Are investors shorting BIOLINERX Ltd/S?
BIOLINERX Ltd/S saw a decrease in short interest in the month of September. As of September 14th, there was short interest totalling 422,263 shares, a decrease of 33.8% from the August 31st total of 638,003 shares. Based on an average trading volume of 255,310 shares, the short-interest ratio is presently 1.7 days. View BIOLINERX Ltd/S's Current Options Chain.
Who are some of BIOLINERX Ltd/S's key competitors?
Some companies that are related to BIOLINERX Ltd/S include Xeris Pharmaceuticals (XERS), Corbus Pharmaceuticals (CRBP), Theratechnologies (THERF), Odonate Therapeutics (ODT), Achillion Pharmaceuticals (ACHN), Minerva Neurosciences (NERV), Zymeworks (ZYME), ZEALAND PHARMA/S (ZEAL), Cytokinetics (CYTK), Aclaris Therapeutics (ACRS), Keryx Biopharmaceuticals (KERX), Zafgen (ZFGN), Urovant Sciences (UROV), Merus (MRUS) and Aquestive Therapeutics (AQST).
Who are BIOLINERX Ltd/S's key executives?
BIOLINERX Ltd/S's management team includes the folowing people:
- Mr. Philip A. Serlin, Chief Exec. Officer (Age 58)
- Ms. Mali Zeevi, CFO & Principal Accounting Officer (Age 42)
- Dr. Ella Sorani, VP R&D (Age 50)
- Dr. Abi Vainstein-Haras M.D., VP of Clinical and Medical Affairs (Age 43)
- Advocate Norman Kotler, Internal Enforcement Officer, Gen. Counsel and Corp. Sec. (Age 66)
How do I buy shares of BIOLINERX Ltd/S?
Shares of BLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BIOLINERX Ltd/S's stock price today?
One share of BLRX stock can currently be purchased for approximately $0.8814.
How big of a company is BIOLINERX Ltd/S?
BIOLINERX Ltd/S has a market capitalization of $104.36 million. The biotechnology company earns $-24,350,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. BIOLINERX Ltd/S employs 51 workers across the globe.
What is BIOLINERX Ltd/S's official website?
How can I contact BIOLINERX Ltd/S?
BIOLINERX Ltd/S's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The biotechnology company can be reached via phone at 972-2548-9100 or via email at [email protected]olinerx.com.
MarketBeat Community Rating for BIOLINERX Ltd/S (NASDAQ BLRX)
MarketBeat's community ratings are surveys of what our community members think about BIOLINERX Ltd/S and other stocks. Vote "Outperform" if you believe BLRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
